Tag: Psilocybin
-
Delic Holdings (DELC.C) emerges as a psychedelics play aimed at executing real, legal business, and right now
Smallcap investors largely see the psychedelics space in one of two ways; you’re either in the ‘this may be big one day but there’s not a lot of fat on the bones just yet so I’ll wait’ camp, or the ‘fat schmat, everything is a trade and who cares about tomorrow’ camp. I’m pegged pretty…
-
Pure Extracts (PULL.C) goes public with profit-focused cannabis (and mushroom) extraction business model
Yeah, I know, I know. Canadian cannabis companies are ass right now, and have been for a few years. Trust me, I’m about as out of the LP business now as I’ve ever been, but you’d also be an idiot to tar every cannabis company with the same brush, because not every deal involves growing…
-
Shroom Digest: Mushroom moves from MindMed, Yield Growth, New Wave, Yukoterre, Silo, EGF Theramed
This week’s digest of mushroom moves is a mixed bag of trash and glory, with the shrooms sector increasingly looking like the early days of the cannabis rush.
-
A Closer Look: ThinkMyco pushes the button on magic mushroom market
Psilocybin and other psychedelics are forcing their way out of prohibition as potentially viable treatments for not only depression and anxiety but also Alzheimer’s and other neurodegenerative diseases plaguing millions in North America alone. In the end, psilocybin solutions address a $300 billion dollar psychotherapy and wellness global market. Shroom Stocks’ own Ethan Reyes spoke…
-
A ‘growing’ concern: With the cannabis bubble bursting, are mushrooms the next gold rush?
“Cannabis is dead; long live cannabis.” Mushrooms, mark my words.. –Ancient potstocks proverb Seriously though, folks, the cannabis sector is in trouble. Take a look at the Horizons Marijuana Life Sciences ETF, a basket of some of the largest cannabis stocks on the market. Here is equity.guru founder, Chris Parry’s take on how the growing pains of…
